New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
10:55 EDTBNNY, USG, DYN, BDSI, IDIX, SLXP, CCIH, ACHN, VIP, NKTRHigh option volume stocks:
High option volume stocks: BNNY VIP ACHN CCIH SLXP IDIX BDSI DYN USG NKTR
News For BNNY;VIP;ACHN;CCIH;SLXP;IDIX;BDSI;DYN;USG;NKTR From The Last 14 Days
Check below for free stories on BNNY;VIP;ACHN;CCIH;SLXP;IDIX;BDSI;DYN;USG;NKTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
August 11, 2014
05:29 EDTACHNAchillion upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information
August 8, 2014
11:16 EDTSLXPSalix post-earnings pullback unwarranted, says Sterne Agee
Subscribe for More Information
09:00 EDTBDSIBioDelivery Sciences still a takeover target, says Janney Capital
Janney Capital continues to believe that BioDelivery Sciences (BDSI) could be a takeover target, noting that it thinks partner Endo International (ENDP) could be a potential buyer if BioDelivery has more positive top-line results and if the market weakens. The firm, which added that it likes BioDelivery Sciences as a stand-alone company as well, maintains its Buy rating and $15 fair value estimate on the stock.
August 7, 2014
18:41 EDTSLXPOn The Fly: After Hours Movers
Subscribe for More Information
17:29 EDTBDSIBioDelivery Sciences sees U.S. launch of Bunavail in late Q3
Subscribe for More Information
17:27 EDTBDSIBioDelivery Sciences reports Q2 EPS (14c), consensus (13c)
Subscribe for More Information
16:53 EDTACHNAchillion reports Q2 EPS (16c), consensus (18c)
President and CEO Milind Deshpande said, "We remain committed to our goal of initiating a Phase 2 trial by the end of 2014, pending regulatory approval, which will evaluate ACH-3422 in combination with ACH-3102 for patients with chronic HCV for treatment durations of eight weeks or less. We also remain confident that our strong balance sheet will fund our operations into 2016." Cash, cash equivalents, marketable securities, and interest receivable as of June 30 were $132.2M.
16:47 EDTBNNYAnnie's backs FY15 adjusted EPS view 88c-95c, consensus 90c
Subscribe for More Information
16:44 EDTBNNYAnnie's reports Q1 EPS (6c), consensus (3c)
Subscribe for More Information
16:16 EDTSLXPSalix sees FY14 EPS $3.16, consensus $6.53
Sees FY14 revenue approximately $1.6B, consensus $1.63B.
16:15 EDTSLXPSalix sees Q3 EPS $1.53, consensus $1.78
Subscribe for More Information
16:14 EDTSLXPSalix reports Q2 EPS $1.59, consensus $1.72
Subscribe for More Information
15:33 EDTSLXP Notable companies reporting after market close
Subscribe for More Information
15:31 EDTSLXPNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include CBS (CBS), consensus 72c; Consolidated Edison (ED), consensus 54c; Monster Beverage (MNST), consensus 75c; News Corporation (NWSA), consensus 3c; NVIDIA (NVDA), consensus 20c; Computer Sciences (CSC), consensus 94c; CareFusion (CFN), consensus 72c;DeVry Education (DV), consensus 67c; Salix Pharmaceuticals (SLXP), consensus $1.72; Federal Realty (FRT), consensus $1.21; SolarCity (SCTY), consensus (99c); Medivation (MDVN), consensus 24c; Sprouts Farmers Market (SFM), consensus 18c; Alnylam Pharmaceuticals (ALNY), consensus (56c); Lions Gate (LGF), consensus 17c; Mercadolibre (MELI), consensus 56c; Post Holdings (POST), consensus 27c; Assured Guaranty (AGO), consensus 35c; Great Plains Energy (GXP), consensus 41c; Air Lease (AL), consensus 52c; Ubiquiti Networks (UBNT), consensus 51c; SemGroup (SEMG), consensus 35c.
07:39 EDTNKTRNektar management to meet with Brean Capital
Subscribe for More Information
August 6, 2014
17:27 EDTDYNDynegy reports Q2 EPS ($1.23), may not compare to consensus (9c)
Reports Q2 revenue $521M, consensus $572.58M. Dynegy’s updated 2014 consolidated adjusted EBITDA guidance range is $330M-$380M, a $30M increase from the previous range of $300M-$350M; and its consolidated 2014 Free Cash Flow guidance range is $45M-$95M which has been increased from the initial range of $10M-$60M.
10:00 EDTSLXPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:13 EDTBDSIBioDelivery Sciences updates ongoing Phase 3 trial for Clonidine Topical Gel
Subscribe for More Information
06:33 EDTSLXPSalix upgraded to Buy from Hold at Cantor
Subscribe for More Information
05:42 EDTVIPVimpelCom reports Q2 EPS 6c vs. 33c last year
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use